Delirium vs. Dementia
Delirium = acute, fluctuating disturbance of ATTENTION and awareness + diffuse background EEG slowing; Dementia = chronic, progressive memory/cognitive decline with preserved alertness.
Alzheimer Disease (AD)
Extracellular β-amyloid (Aβ42) neuritic plaques + intracellular hyperphosphorylated tau neurofibrillary tangles; APOE ε4 risk; early APP (chr 21 / Down), PSEN1, PSEN2.
Frontotemporal Dementia (Pick)
Age 45–65; early personality/behavioral disinhibition, apathy, hyperorality, or primary progressive aphasia; Pick bodies (3R tau) or TDP-43 (linked to ALS).
Dementia with Lewy Bodies (DLB)
Cognitive decline BEFORE or within 1 year of parkinsonism + well-formed visual hallucinations, REM sleep behavior disorder, fluctuating alertness; avoid D2 antipsychotics!
Normal Pressure Hydrocephalus
'Wet, Wacky, Wobbly' (magnetic/apraxic gait FIRST, urinary incontinence, reversible dementia); enlarged ventricles with normal LP opening pressure; VP shunt.
Creutzfeldt-Jakob Disease (CJD)
Prion conformational conversion (PrPc α-helix → PrPsc β-pleated sheet); rapidly progressive dementia + startle myoclonus + CSF 14-3-3 / RT-QuIC + 1–2 Hz periodic sharp wave complexes.
Wernicke-Korsakoff Syndrome
Thiamine (B1) deficiency damaging mammillary bodies & mediodorsal thalamus; Wernicke triad (confusion, ophthalmoplegia, ataxia); ALWAYS give IV Thiamine BEFORE Glucose!
Pseudodementia (Depression)
Elderly patient with acute onset cognitive complaints, distressed by memory loss, answers 'I don't know' with poor effort on MMSE; resolves with SSRI therapy.
Dementia Subtypes Differential Matrix
Major Neurocognitive Disorders (Dementia) are chronic, insidious neurodegenerative or vascular syndromes characterized by progressive decline in ≥1 cognitive domain (memory, executive function, language, visuospatial ability, or social cognition) that interferes with independent Instrumental Activities of Daily Living (IADLs) in the presence of a CLEAR sensorium/level of consciousness (distinguishing dementia from acute, fluctuating Delirium). Chronological symptom order and neuroimaging localization separate the five major dementia subtypes.
| Dementia Type | Pathology & Neuroimaging | Clinical Presentation Hallmark | Pharmacologic Management |
|---|---|---|---|
| Alzheimer Disease (AD) | Extracellular Amyloid-beta plaques and intracellular hyperphosphorylated Tau neurofibrillary tangles; hippocampal and temporoparietal atrophy | Early, prominent short-term memory impairment (anterograde amnesia) with preserved remote memory; progressive loss of executive function | Cholinesterase inhibitors (Donepezil, Rivastigmine, Galantamine); NMDA receptor antagonist (Memantine) |
| Vascular Dementia | Large vessel atherothrombosis or small vessel lacunar infarcts; subcortical white matter ischemic changes | Stepwise cognitive deterioration temporally linked to previous transient ischemic attacks or strokes; focal neurologic deficits | Control cardiovascular risk factors (antihypertensives, statins, antiplatelet therapy); smoking cessation |
| Dementia with Lewy Bodies (DLB) | Cortical cytoplasmic alpha-synuclein Lewy bodies | Visual hallucinations (well-formed people/animals), spontaneous Parkinsonism, fluctuating alertness/attention, REM sleep behavior disorder | Cholinesterase inhibitors (Donepezil); AVOID typical antipsychotics (severe neuroleptic hypersensitivity) |
| Frontotemporal Dementia (Pick Disease) | Intracellular aggregates of hyperphosphorylated tau (Pick bodies) or TDP-43; focal frontal and temporal lobar atrophy | Early personality and behavioral changes (disinhibition, apathy, hyperorality), loss of empathy, followed by expressive progressive aphasia; memory spared early | Supportive care; SSRIs for compulsive behaviors; atypical antipsychotics used with extreme caution |
Alzheimer Disease (APOE-e4, APP Chromosome 21, Beta-Amyloid & Tau) vs. Vascular Dementia (Stepwise Decline)
Alzheimer Disease (AD) accounts for 60%–80% of all dementia cases and presents insidiously with anterograde episodic memory loss (inability to recall recent conversations or events while remote childhood memories remain intact), progressing over years to visuospatial disorientation (getting lost in familiar neighborhoods), language apraxia, and complete loss of basic ADLs. Pathologically, AD is driven by loss of basal forebrain cholinergic neurons in the Nucleus Basalis of Meynert and hippocampal/cortical atrophy (causing secondary hydrocephalus ex vacuo), with two microscopic hallmarks: extracellular Neuritic Plaques composed of Aβ42 amyloid (generated by β- and γ-secretase cleavage of Amyloid Precursor Protein [APP]; these also deposit in cerebral blood vessels to cause Cerebral Amyloid Angiopathy [CAA] and recurrent lobar intracerebral hemorrhages in the elderly!) and intracellular Neurofibrillary Tangles composed of hyperphosphorylated Tau protein. Genetic risk factors include Early-Onset Familial AD (<60 years) caused by autosomal dominant mutations in APP (Chromosome 21), PSEN1 (Presenilin-1, Chromosome 14), or PSEN2 (Chromosome 1)—explaining why patients with Down Syndrome (Trisomy 21) carry three copies of the APP gene and universally develop Alzheimer pathology by age 40–50!—and Late-Onset Sporadic AD associated with the APOE-ε4 allele (whereas APOE-ε2 is protective). Symptomatic pharmacotherapy uses Acetylcholinesterase Inhibitors (Donepezil, Rivastigmine, Galantamine; watch for cholinergic GI nausea/diarrhea and sinus bradycardia/syncope) plus the NMDA receptor antagonist Memantine for moderate-to-severe AD. Conversely, Vascular (Multi-Infarct) Dementia (#2 cause of dementia) occurs in patients with hypertension, atrial fibrillation, and diabetes, presenting with an abrupt, 'stepwise' cognitive decline accompanied by early executive dysfunction and focal neurological deficits (extensor plantar response, gait asymmetry, pseudobulbar palsy) and multiple cortical or subcortical white-matter infarcts on MRI.
Dementia with Lewy Bodies (1-Year Rule & Visual Hallucinations), Frontotemporal Dementia (Pick) & Normal Pressure Hydrocephalus
The remaining three dementia syndromes are tested via their chronological and behavioral signatures: (1) Dementia with Lewy Bodies (DLB) (#3 cause of dementia; cortical intracellular α-synuclein Lewy bodies) presents with dementia accompanied by ≥2 of 4 core features: vivid, well-formed VISUAL HALLUCINATIONS (e.g., seeing small children or animals in the room), fluctuating cognition/alertness, spontaneous Parkinsonism, and REM Sleep Behavior Disorder. THE 1-YEAR RULE: If cognitive decline/dementia begins before or within 1 year of parkinsonian motor symptoms, the diagnosis is Dementia with Lewy Bodies (DLB); if motor parkinsonism exists for >1 year before dementia develops, the diagnosis is Parkinson Disease Dementia (PDD)! Crucially, avoid first-generation and high-potency D2-blocking antipsychotics (haloperidol) in DLB because extreme neuroleptic sensitivity triggers fatal rigidity and NMS! (2) Frontotemporal Dementia (FTD / Pick Disease) presents in younger patients (ages 45–65) with early, dramatic personality and behavioral disinhibition (inappropriate sexual/social comments, apathy, loss of empathy, hyperorality/compulsive eating of sweets) OR primary progressive aphasia, while visuospatial function and early memory remain relatively spared; MRI shows striking knife-edge atrophy of the Frontal and Temporal lobes, and histology shows phosphorylated Tau (Pick bodies: round argyrophilic neuronal inclusions) or TDP-43. (3) Normal Pressure Hydrocephalus (NPH) is a reversible communicating hydrocephalus (impaired CSF absorption at the arachnoid granulations with enlarged ventricles out of proportion to sulcal atrophy and normal CSF opening pressure on LP) presenting with the classic triad of 'Wet, Wacky, and Wobbly': Gait Apraxia ('magnetic' feet stuck to the floor—ALWAYS the first symptom to appear and the first to improve!), Urinary Incontinence, and Cognitive Dementia; diagnose with a high-volume (30–50 mL) Lumbar Puncture tap test (Miller Fisher test) and treat definitively with a Ventriculoperitoneal (VP) Shunt!
Delirium vs. Dementia vs. Depressive Pseudodementia Master Matrix & Beers Criteria
When an older adult presents with acute or subacute cognitive decline, the clinician's immediate priority is differentiating Delirium (a medical emergency with 10–25% inpatient mortality), Major Neurocognitive Disorder (Dementia), and Depressive Pseudodementia. The single most reliable bedside discriminator between delirium and dementia is ATTENTION and LEVEL OF CONSCIOUSNESS: a delirious patient exhibits an acute (hours to days), waxing-and-waning inability to focus, sustain, or shift attention (e.g., failing to spell 'WORLD' backward or recite the months of the year in reverse), whereas a patient with uncomplicated mild-to-moderate dementia remains wide awake, alert, and attentive despite profound deficits in short-term recall and executive function.
| Clinical Feature | Delirium (Acute Confusional State) | Dementia (Major Neurocognitive Disorder) | Depressive Pseudodementia |
|---|---|---|---|
| Onset & Course | Acute (hours to days); waxing and waning throughout the day (nocturnal sundowning) | Insidious (months to years); chronically progressive and irreversible | Subacute (weeks to months); often linked to bereavement or depression history |
| Level of Consciousness & Attention | Impaired alertness (hypervigilant or lethargic) and severe INATTENTION | Normal alertness and attention until late-stage disease | Normal alertness; subjective poor concentration due to apathy |
| Patient Attitude & Testing Behavior | Agitated, fearful, perplexed, or somnolent; visual/tactile hallucinations common | Unconcerned (anosognosia); tries hard on MMSE but makes near-miss errors | Distressed by memory loss; poor effort, answers 'I don't know' on MMSE |
| EEG & Neuroimaging | Diffuse generalized background slowing on EEG; neuroimaging normal | Normal EEG early; MRI shows cortical/hippocampal atrophy or vascular infarcts | Normal EEG and normal Brain MRI |
| First-Line Management | Treat underlying medical cause + stop anticholinergics/benzos + reorientation (low-dose Haloperidol ONLY if dangerous) | Acetylcholinesterase inhibitors (Donepezil, Rivastigmine, Galantamine) + Memantine | SSRI antidepressant (Sertraline, Citalopram) or ECT → complete cognitive recovery |
Delirium Pathophysiology, Precipitants, EEG Slowing & First-Line Management
Delirium represents acute global cerebral cortical dysfunction driven by a central cholinergic deficiency coupled with dopaminergic excess and systemic neuroinflammation. It manifests across three clinical subtypes: hyperactive (agitation, hypervigilance, pulling out IV lines, visual/tactile hallucinations), hypoactive (lethargy, psychomotor retardation, Somnolence—the most common and most frequently missed subtype in hospitalized elderly patients!), and mixed (classic nocturnal worsening or 'sundowning'). In contrast to normal aging or early Alzheimer disease, the electroencephalogram (EEG) in delirium demonstrates generalized diffuse background slowing (theta and delta waves) (except in alcohol/benzodiazepine withdrawal delirium tremens, which shows fast beta activity). Common precipitants in elderly patients include occult infection (UTI, pneumonia), polypharmacy/anticholinergic toxicity, dehydration, hyponatremia, hypoxia, urinary retention, and fecal impaction. First-line management of delirium is ALWAYS identifying and reversing the underlying medical trigger plus non-pharmacologic environmental reorientation (opening blinds during the day, maintaining quiet dark rooms at night, providing eyeglasses and hearing aids, early mobilization, removing unnecessary urinary catheters and physical restraints). Low-dose Haloperidol (or atypical antipsychotics such as quetiapine in Parkinson/DLB patients) is reserved strictly for severe agitation where the patient poses an imminent physical danger to self or staff; NEVER administer benzodiazepines (lorazepam) for non-withdrawal elderly delirium, as benzodiazepines paradoxically worsen confusion and prolong delirium!
Beers Criteria High-Risk Deliriogenic Medications in the Elderly
Board examinations frequently present an elderly patient who becomes acutely confused 48 hours after starting a routine outpatient or inpatient medication. According to the AGS Beers Criteria, medications with potent central antimuscarinic (anticholinergic) activity cross the blood-brain barrier and block M1 acetylcholine receptors in the hippocampus and prefrontal cortex, precipitating acute delirium, urinary retention, constipation, blurry vision, and falls. The highest-yield culprits to eliminate immediately on medication reconciliation include: (1) First-generation H1-antihistamines (diphenhydramine [often hidden in over-the-counter 'PM' sleep aids], hydroxyzine, chlorpheniramine, promethazine); (2) Tricyclic Antidepressants (TCAs) (amitriptyline, nortriptyline, doxepin, imipramine); (3) Bladder antimuscarinics (oxybutynin, tolterodine, solifenacin) and GI antispasmodics (dicyclomine, hyoscyamine, scopolamine); (4) Low-potency antipsychotics (chlorpromazine, thioridazine) and benztropine/trihexyphenidyl; and (5) Benzodiazepines (alprazolam, diazepam, lorazepam), Z-hypnotics (zolpidem), opioid analgesics (especially meperidine), and H2-blockers (famotidine/cimetidine).
Depressive Pseudodementia vs. True Neurodegenerative Dementia
In Depressive Pseudodementia (Cognitive Syndrome of Late-Life Depression), an elderly patient with Major Depressive Disorder presents with prominent memory, concentration, and executive complaints that closely mimic early Alzheimer disease. Several high-yield clinical features reliably distinguish pseudodementia from true neurodegenerative dementia: (1) Onset is relatively rapid and subacute (weeks to months) with an identifiable date of onset (often following a major life stressor or bereavement), whereas Alzheimer dementia is insidious over years; (2) Patients with pseudodementia are acutely aware of and deeply distressed by their cognitive lapses, frequently complaining of how terrible their memory is, whereas Alzheimer patients typically minimize, confabulate, or remain unaware of their deficits (anosognosia) and are brought in by concerned family members; (3) On cognitive testing (MMSE/MoCA), depressed patients exhibit poor effort and apathy, repeatedly answering 'I don't know' without trying, whereas demented patients try hard and give near-miss or incorrect answers; and (4) Aphasia, apraxia, agnosia, and nocturnal sundowning are ABSENT in pseudodementia, and cognitive function completely normalizes following an adequate trial of an SSRI antidepressant (e.g., sertraline, escitalopram) or electroconvulsive therapy (ECT).
Neuropathology, Genetics, Biomarkers & Pharmacology of Major Dementias (AD, VaD, FTD, DLB)
While Alzheimer Disease (AD) accounts for 60–80% of all late-life dementias, board vignettes rigorously test the histopathological hallmarks, genetic mutations, sequential symptom progression, and neurotransmitter pharmacology that distinguish AD, Vascular Dementia (VaD), Frontotemporal Dementia (FTD), and Dementia with Lewy Bodies (DLB).
| Dementia Subtype | Earliest Clinical Presentation | Neuroimaging & Anatomic Distribution | Pathognomonic Histopathology & Genetics | High-Yield Pharmacology & Board Pearls |
|---|---|---|---|---|
| Alzheimer Disease (AD) | Insidious short-term anterograde memory loss → language/visuospatial → personality | Diffuse cortical atrophy, disproportionately severe in hippocampus & medial temporal lobes | Extracellular Aβ42 plaques + Intracellular hyperphosphorylated Tau tangles; APOE ε4, APP (chr 21), PSEN1/2 | Donepezil / Rivastigmine / Galantamine + Memantine; CAA causes lobar hemorrhage |
| Vascular Dementia (VaD) | Abrupt 'stepwise' decline + early executive dysfunction + focal neurological deficits (Babinski+, gait) | Multiple cortical infarcts or diffuse periventricular white matter T2 hyperintensities | Hyaline arteriolosclerosis, lipohyalinosis, cystic infarcts with reactive gliosis | Strict BP, diabetes, statin, and antiplatelet/anticoagulation stroke secondary prevention |
| Frontotemporal Dementia (FTD / Pick) | Age 45–65; Early behavioral disinhibition, apathy, hyperorality, or primary progressive aphasia (memory spared early!) | Severe 'knife-edge' atrophy of frontal & anterior temporal lobes | Pick bodies (round silver-staining Tau) or TDP-43; C9orf72 (linked to ALS) | SSRIs (trazodone/sertraline) for compulsive/disinhibited behavior (AChE inhibitors ineffective!) |
| Dementia with Lewy Bodies (DLB) | Visual hallucinations + fluctuating alertness + REM sleep behavior disorder + parkinsonism (≤ 1 yr) | Generalized atrophy with preserved medial temporal lobes; reduced striatal DaTscan uptake | Cortical & brainstem eosinophilic intracytoplasmic α-synuclein Lewy bodies | Rivastigmine / Donepezil; NEVER give Haloperidol/D2 blockers (fatal rigidity!) |
Alzheimer Disease: Amyloid Precursor Protein, Tau Tangles, APOE4, CAA & Pharmacology
Alzheimer Disease (AD) presents insidiously with anterograde episodic memory loss (inability to learn new information, repeating questions, misplacing objects) caused by early degeneration of the hippocampus and entorhinal cortex, coupled with selective loss of cholinergic neurons in the nucleus basalis of Meynert (where choline acetyltransferase [ChAT] activity drops precipitously). Over years, pathology spreads to the temporoparietal association cortex (producing visuospatial disorientation/getting lost, language impairment, and ideomotor apraxia) and eventually the frontal lobes (personality change, mutism, bedbound dysphagia). Gross brain pathology reveals diffuse cortical atrophy (narrowed gyri, widened sulci, and hydrocephalus ex vacuo) that is most pronounced in the medial temporal lobes/hippocampi. Microscopic histology demonstrates two signature lesions: (1) Extracellular Neuritic (Senile) Plaques composed of a central amyloid core of Aβ42 peptide generated when Amyloid Precursor Protein (APP) is cleaved sequentially by β-secretase and γ-secretase instead of non-amyloidogenic α-secretase; Aβ also deposits in leptomeningeal and cortical arterial walls as Cerebral Amyloid Angiopathy (CAA), which stains apple-green birefringent with Congo red and causes recurrent spontaneous LOBAR intracerebral hemorrhages in normotensive elderly patients! (2) Intracellular Neurofibrillary Tangles (NFTs), flame-shaped intraneuronal bundles of hyperphosphorylated tau protein (a microtubule-associated protein; crucially, the density of neurofibrillary tau tangles—NOT amyloid plaques—correlates directly with clinical dementia severity), alongside eosinophilic Hirano bodies in the hippocampus. Genetically, Sporadic Late-Onset AD (> 65 yr, 95%) is strongly associated with the APOE ε4 allele on chromosome 19 (which impairs Aβ clearance, whereas APOE ε2 is protective!); Early-Onset Familial AD (< 60 yr) is caused by autosomal dominant mutations in Presenilin-1 (PSEN1, chr 14) or Presenilin-2 (PSEN2, chr 1) (catalytic subunits of γ-secretase) or APP on chromosome 21 (explaining why Down syndrome [Trisomy 21] patients universally develop early-onset Alzheimer pathology by age 40!). CSF biomarkers show decreased CSF Aβ42 (trapped in brain plaques) and increased CSF phosphorylated tau. First-line symptomatic medications are central acetylcholinesterase inhibitors—Donepezil, Rivastigmine, and Galantamine (which cause GI nausea/diarrhea and sinus bradycardia/syncope) plus Memantine (an uncompetitive NMDA glutamate receptor antagonist that blocks Ca2+-mediated excitotoxicity in moderate-to-severe AD); anti-amyloid monoclonal antibodies (Lecanemab, Donanemab) clear Aβ plaques in early AD but require MRI monitoring for ARIA (amyloid-related imaging abnormalities: cerebral edema and microhemorrhages).
Vascular Dementia (Stepwise Decline) vs. Frontotemporal Dementia (Pick Bodies / TDP-43)
(1) Vascular Dementia (VaD) is the second most common dementia overall, occurring in patients with chronic poorly controlled hypertension, diabetes mellitus, smoking, or atrial fibrillation. It is caused either by multiple cortical embolic infarcts (multi-infarct dementia) or diffuse chronic small-vessel lipohyalinosis of deep penetrating white matter arteries (Binswanger disease / subcortical leukoaraiosis). The classic board presentation is an abrupt, 'STEPWISE' cognitive deterioration (where the patient plateaus after a stroke and then suddenly drops to a lower baseline after a subsequent infarct) accompanied by early executive dysfunction, gait disturbance, pseudobulbar affect, and focal upper motor neuron signs (extensor Babinski sign, asymmetric hyperreflexia, hemiparesis) with multifocal T2 hyperintensities and old lacunar infarcts on MRI. (2) Frontotemporal Dementia (FTD / Pick Disease) presents earlier than AD (typically age 45–65) with selective 'knife-edge' atrophy of the frontal and anterior temporal lobes (sparing the parietal and occipital lobes!). Because the hippocampus is initially spared, visuospatial skills and episodic memory remain relatively intact early on. Instead, FTD presents as either the Behavioral Variant (bvFTD)—marked by early socially inappropriate disinhibition (lewd remarks, shoplifting, poor hygiene), profound apathy/blunted affect, compulsive rituals, and hyperorality (binge eating sweets/carbohydrates)—or Primary Progressive Aphasia (PPA) (non-fluent effortful speech or semantic loss of word meaning). Histopathology reveals either round argyrophilic intraneuronal inclusions of hyperphosphorylated 3-repeat tau (Pick bodies) and swollen achromatic Pick cells, or ubiquitinated TDP-43 inclusions (especially in familial FTD caused by C9orf72 hexanucleotide repeat expansions, which co-occurs with Amyotrophic Lateral Sclerosis [ALS]!).
Dementia with Lewy Bodies (DLB): Visual Hallucinations, REM Sleep Disorder & Neuroleptic Sensitivity
Dementia with Lewy Bodies (DLB) is the third most common degenerative dementia and is caused by widespread cortical and brainstem accumulation of intracellular eosinophilic α-synuclein inclusions (Lewy bodies). By strict clinical consensus criteria (the '1-Year Rule'), DLB is diagnosed when dementia begins BEFORE or within 1 year of the onset of parkinsonian motor symptoms (whereas Parkinson Disease Dementia [PDD] is diagnosed when dementia develops > 1 year—typically 5–10+ years—after established Parkinson disease). Beyond dementia, DLB is defined by four core diagnostic features: (1) Recurrent, vivid, well-formed visual hallucinations (e.g., seeing small children, animals, or strangers sitting quietly in the living room—often the earliest presenting symptom!); (2) Fluctuating cognition with pronounced variations in attention and alertness from day to day (mimicking delirium); (3) REM Sleep Behavior Disorder (RBD) (loss of normal pontine REM muscle atonia causing the patient to violently act out dreams, kicking and punching in bed, often preceding dementia by years); and (4) Spontaneous Parkinsonism (symmetric bradykinesia, rigidity, and shuffling gait with frequent falls). First-line treatment for both cognitive impairment and visual hallucinations in DLB is an acetylcholinesterase inhibitor (Rivastigmine or Donepezil). A critical board red flag is severe neuroleptic (antipsychotic) sensitivity: administering D2 receptor antagonists (haloperidol, risperidone) in DLB triggers catastrophic, irreversible akinetic-rigid parkinsonism, neuroleptic malignant syndrome, and death!
Reversible Dementia Workup & Normal Pressure Hydrocephalus ('Wet, Wacky, Wobbly')
Up to 10% of patients evaluated for suspected dementia harbor a potentially reversible metabolic, endocrine, infectious, or structural etiology. Consequently, the American Academy of Neurology mandates a standardized initial diagnostic workup for every patient presenting with cognitive decline before assigning an irreversible neurodegenerative diagnosis.
| Reversible Dementia Etiology | Pathophysiological Mechanism | Classic Clinical Clues | Definitive Diagnostic Test & Cure |
|---|---|---|---|
| Normal Pressure Hydrocephalus (NPH) | Impaired arachnoid granulation CSF absorption → stretching of periventricular corona radiata | 'Wet, Wacky, Wobbly' (magnetic gait apraxia 1st, urinary incontinence, frontal dementia) | MRI: ventriculomegaly WITHOUT proportional sulcal atrophy; Large-volume LP tap test → VP Shunt |
| Vitamin B12 Deficiency | Impaired methionine synthase & methylmalonyl-CoA mutase → defective myelin synthesis | Cognitive decline + loss of vibration/proprioception (dorsal columns) + spastic paresis (lateral corticospinal) + glossitis | Low serum B12, elevated Methylmalonic Acid (MMA), macrocytic anemia; Rx: IM/high-dose Vitamin B12 |
| Hypothyroidism | Deficient thyroid hormone metabolic/transcriptional activity in CNS | Psychomotor slowing, memory loss, cold intolerance, weight gain, hung-up delayed DTR relaxation | Elevated TSH, low free T4; Rx: Levothyroxine |
| Chronic Subdural Hematoma | Rupture of bridging cortical veins (elderly/alcoholic cortical atrophy stretching veins) | Subacute fluctuating headache, confusion, personality change, mild hemiparesis weeks after minor fall | Non-contrast Head CT: crescent-shaped hypodense collection crossing suture lines; Rx: Burr hole evacuation |
| Neurosyphilis (Treponema pallidum) | Chronic meningovascular and parenchymal spirochete invasion (tabes dorsalis / general paresis) | Personality change, dementia, Argyll Robertson pupils (accommodates but does NOT react to light), tabetic ataxia | Serum RPR/FTA-ABS + CSF VDRL + pleocytosis; Rx: 10–14 days IV Aqueous Crystalline Penicillin G |
Interactive 2K Master Atlas Plate
Mandatory Initial Reversible Dementia Screening Panel (B12, TSH, Syphilis, Subdural)
Every patient presenting with new-onset dementia must undergo: (1) Serum Vitamin B12 (cobalamin) level (and methylmalonic acid/homocysteine if borderline; B12 deficiency causes reversible megaloblastic anemia, subacute combined degeneration of the dorsal columns and lateral corticospinal tracts, and dementia); (2) Serum Thyroid-Stimulating Hormone (TSH) and free T4 (hypothyroidism causes psychomotor slowing, memory impairment, weight gain, constipation, and delayed relaxation of deep tendon reflexes); (3) Complete Blood Count (CBC), Comprehensive Metabolic Panel (CMP: Na+, Ca2+, renal/hepatic function); (4) Non-contrast Structural Neuroimaging (Brain MRI or Head CT) to rule out a chronic subdural hematoma (tearing of bridging veins after minor head trauma in an elderly or alcoholic patient, showing a crescent-shaped hypodense collection crossing suture lines), frontal lobe meningioma, or Normal Pressure Hydrocephalus; and (5) HIV serology and RPR/treponemal syphilis testing (for neurosyphilis) in patients with risk factors or atypical young-onset dementia.
Normal Pressure Hydrocephalus (NPH): Pathophysiology, Triad & Gait Sequence
Normal Pressure Hydrocephalus (NPH) is a potentially reversible communicating (non-obstructive) hydrocephalus in adults aged > 60 caused by impaired CSF reabsorption at the arachnoid granulations (either idiopathic or secondary to prior subarachnoid hemorrhage, meningitis, or head trauma). It presents with the classic clinical triad of 'Wet, Wacky, and Wobbly': (1) Gait Apraxia ('Wobbly' — ALWAYS the FIRST and most prominent symptom to appear, and the FIRST symptom to improve after treatment!): patients exhibit a broad-based, slow, small-stepped 'MAGNETIC GAIT' in which the feet appear glued to the floor, despite completely normal leg strength and coordination when tested lying supine in bed (Bruns frontal gait apraxia). (2) Urinary Incontinence ('Wet'): stretching of the periventricular corona radiata sacral motor fibers that travel closest to the lateral ventricles removes tonic frontal inhibition of the pontine micturition center, causing early urinary urgency and detrusor overactivity incontinence (with lack of concern in late stages). (3) Subcortical Frontal Dementia ('Wacky'): psychomotor slowing, apathy, executive dysfunction, and impaired recall.
NPH Neuroimaging (Hydrocephalus Ex Vacuo Differentiation), Miller Fisher Tap Test & VP Shunt
The major diagnostic trap on neuroimaging is distinguishing Normal Pressure Hydrocephalus from Hydrocephalus Ex Vacuo (compensatory ventricular enlargement secondary to diffuse cortical atrophy in Alzheimer or Huntington disease). On Brain MRI/CT, NPH demonstrates ventriculomegaly that is DISPROPORTIONATELY LARGE relative to the degree of cortical sulcal enlargement (Evans index > 0.3, narrowing of the high-convexity subarachnoid spaces, steep callosal angle, and periventricular T2 hyperintensity from transependymal CSF seepage), whereas hydrocephalus ex vacuo shows enlarged ventricles accompanied by prominent cortical atrophy (widened sulci and shrunken gyri). The definitive diagnostic and prognostic test for NPH is the High-Volume Lumbar Puncture ('Miller Fisher Tap Test'): CSF opening pressure is normal (80–200 mm H2O) with normal cell counts and protein, and removing 30–50 mL of CSF produces an immediate, measurable improvement in timed walking speed and stride length within 30–60 minutes. Patients with a positive tap test undergo permanent surgical CSF diversion via a Ventriculoperitoneal (VP) Shunt.
Prion Diseases (Creutzfeldt-Jakob Disease) & Wernicke-Korsakoff Syndrome
When a patient presents with rapidly progressive dementia evolving over weeks to a few months (rather than years), the differential diagnosis narrows immediately to Prion Disease (Creutzfeldt-Jakob Disease), autoimmune/paraneoplastic limbic encephalitis (e.g., anti-NMDA receptor encephalitis), Wernicke-Korsakoff syndrome, and metabolic/infectious encephalopathies.
| Rapidly Progressive Encephalopathy | Molecular / Pathologic Mechanism | Classic Clinical Triad & Neuro Exam | Pathognomonic Diagnostic Findings | Immediate Management Protocol |
|---|---|---|---|---|
| Creutzfeldt-Jakob Disease (CJD) | PrPc (α-helix) → PrPsc (β-pleated sheet); spongiform vacuoles (no inflammation) | Rapidly progressive dementia (weeks–months) + Startle Myoclonus + Ataxia | CSF RT-QuIC / 14-3-3 protein; EEG 1–2 Hz periodic sharp waves; MRI cortical ribboning | Supportive care (100% fatal within 1 year); special prion instrument decontamination |
| Wernicke Encephalopathy | Thiamine (Vitamin B1) deficiency → hemorrhagic necrosis of mammillary bodies | Encephalopathy + Oculomotor palsy (CN VI / nystagmus) + Gait Ataxia | MRI T2 hyperintensity in mammillary bodies, periaqueductal gray, medial thalami; ↓ RBC transketolase | High-dose IV Thiamine BEFORE IV Glucose! (triad reverses: eye signs 1st, ataxia 2nd, confusion 3rd) |
| Korsakoff Amnestic Syndrome | Chronic irreversible damage to mammillary bodies & mediodorsal/anterior thalamus (Papez circuit) | Severe anterograde > retrograde amnesia + Confabulation + apathy (normal alertness) | Mammillary body atrophy on Brain MRI | Long-term thiamine supplementation, alcohol cessation, structured memory care (mostly irreversible) |
| Anti-NMDA Receptor Encephalitis | IgG autoantibodies internalizing postsynaptic GluN1 NMDA glutamate receptors | Young female: acute psychosis/hallucinations + seizures + orofacial dyskinesias + dysautonomia | CSF anti-NMDAR IgG antibodies; Pelvic US/MRI showing Ovarian Teratoma (50%) | Surgical resection of ovarian teratoma + IV Methylprednisolone + IVIG / Plasmapheresis |
| Hepatic Encephalopathy | Hyperammonemia (NH3) → astrocyte glutamine osmotic swelling & GABA tone | Cirrhosis + Asterixis (flapping tremor) + confusion / coma + fetor hepaticus | Clinical diagnosis; EEG shows generalized triphasic waves | Correct precipitant (GI bleed, hypokalemia, infection) + Lactulose + Rifaximin |
Creutzfeldt-Jakob Disease (CJD): PrPsc Beta-Pleated Sheet Conversion, Myoclonus, 14-3-3 & RT-QuIC
Creutzfeldt-Jakob Disease (CJD) is an invariably fatal transmissible spongiform encephalopathy (100% mortality, typically within 6–12 months of symptom onset). It is caused by a conformational shift of the normal host cellular prion protein PrPc (predominantly α-helical, protease-sensitive) into the pathogenic scrapie isoform PrPsc (predominantly β-pleated sheet conformation). Once present, PrPsc acts as a physical template that recruits and converts native PrPc molecules into PrPsc, forming insoluble neurotoxic aggregates that are completely resistant to host proteases, standard hospital autoclaving, formaldehyde, ethanol, and ionizing radiation. Roughly 85% of cases are sporadic (sCJD, peak age 60–70), 10–15% are familial (PRNP gene mutation on chromosome 20, which also causes Fatal Familial Insomnia via thalamic degeneration), and < 1% are acquired (iatrogenic transmission via corneal transplants, dural grafts, cadaveric human growth hormone, or neurosurgical instruments; or variant CJD [vCJD] transmitted by ingesting beef contaminated with Bovine Spongiform Encephalopathy ['mad cow disease'] in younger patients presenting with early psychiatric symptoms and pulvinar sign on MRI). Clinically, sCJD presents with the classic triad of rapidly progressive dementia (weeks to months), startle myoclonus (sudden jerky muscle contractions provoked by a loud clap or noise), and cerebellar ataxia / visual disturbances / akinetic mutism. Diagnostic confirmation relies on three high-yield tests: (1) CSF analysis showing positive Real-Time Quaking-Induced Conversion (RT-QuIC — the most specific test!) and elevated 14-3-3 protein / tau; (2) EEG demonstrating 1–2 Hz generalized periodic sharp wave (biphasic/triphasic) complexes; and (3) Diffusion-Weighted Brain MRI (DWI) showing asymmetric 'cortical ribboning' hyperintensity and basal ganglia (caudate/putamen) hyperintensity. Brain biopsy/autopsy reveals spongiform encephalopathy—innumerable microscopic intracytoplasmic vacuoles within neurons and neuropil creating a 'Swiss cheese' sponge-like appearance, profound neuronal loss, and astrocytic gliosis WITHOUT any inflammatory leukocyte infiltrate!
Wernicke Encephalopathy vs. Korsakoff Syndrome: Mammillary Bodies & Thiamine-Before-Glucose Rule
Thiamine (Vitamin B1)—in its active phosphorylated form thiamine pyrophosphate (TPP)—is an obligatory cofactor for four key enzymes of carbohydrate metabolism ('ATP-B'): Pyruvate dehydrogenase (linking glycolysis to the TCA cycle), α-Ketoglutarate dehydrogenase (TCA cycle), Transketolase (HMP shunt), and Branched-chain α-ketoacid dehydrogenase. In patients with chronic alcohol use disorder, hyperemesis gravidarum, anorexia nervosa, bariatric surgery, or prolonged TPN without vitamin supplementation, thiamine depletion causes ATP failure, focal lactic acidosis, and petechial hemorrhagic necrosis of the mammillary bodies, periaqueductal gray matter, and mediodorsal nucleus of the thalamus. (1) Wernicke Encephalopathy (Acute & Reversible) presents with the classic triad of Confusion/Encephalopathy, Oculomotor Dysfunction (horizontal nystagmus, bilateral CN VI lateral rectus palsies, conjugate gaze palsy), and Truncal Gait Ataxia. CRITICAL EMERGENCY RULE: In any malnourished, alcoholic, or obtunded patient presenting to the ED, ALWAYS administer parenteral IV Thiamine (100–500 mg) BEFORE or concurrently with any IV Dextrose/Glucose infusion! Infusing glucose first accelerates glycolysis, rapidly consuming the body's last remaining TPP stores and precipitating acute, irreversible Wernicke encephalopathy or cardiovascular wet beriberi! (2) Korsakoff Syndrome (Chronic & Largely Irreversible) develops in untreated Wernicke patients due to permanent destruction of the bilateral mammillary bodies and anterior/mediodorsal thalamic nuclei (Papez circuit), presenting with profound anterograde and retrograde amnesia (with preserved working/procedural memory and normal alertness) accompanied by confabulation (unconsciously fabricating detailed, plausible stories to fill in memory gaps without intent to deceive) and apathy.
Hepatic Encephalopathy, Uremic Encephalopathy & Autoimmune (Anti-NMDA) Encephalitis
Three additional rapidly reversible or subacute encephalopathies are frequently contrasted with CJD and Wernicke syndrome: (1) Hepatic Encephalopathy occurs in decompensated cirrhosis (precipitated by GI bleeding, hypokalemia/alkalosis, infection, constipation, or TIPS placement) when gut-derived ammonia (NH3) bypasses the liver and crosses the blood-brain barrier, where astrocytes convert glutamate + NH3 into osmotically active glutamine (causing astrocyte swelling and GABAergic neuroinhibition); it presents with asterixis ('flapping tremor' on wrist extension), sleep-wake reversal, and triphasic waves on EEG, and is treated with lactulose (acidifies colon to trap NH4+) plus rifaximin. (2) Autoimmune Anti-NMDA Receptor Encephalitis classically affects young women with an underlying ovarian teratoma, presenting with a viral-like prodrome followed rapidly by acute psychosis/paranoia, memory loss, seizures, orofacial dyskinesias, and autonomic instability; treat with ovarian teratoma resection + IV corticosteroids, IVIG, or plasmapheresis. (3) Subacute Sclerosing Panencephalitis (SSPE) is a fatal, slow neurodegenerative complication occurring 7–10 years after early childhood measles (rubeola) infection due to mutated defective measles virus persistence in the CNS, presenting in a school-aged child with declining academic performance, personality change, myoclonic jerks, and elevated CSF anti-measles IgG oligoclonal bands.
Neuroimaging Signatures, CSF Biomarkers & Behavioral/Pharmacologic Management
Modern evaluation of neurocognitive disorders integrates structural neuroimaging (non-contrast CT or brain MRI), cerebrospinal fluid (CSF) or amyloid/tau PET biomarkers, and targeted pharmacotherapy while strictly avoiding anticholinergic or sedative agents that precipitate acute delirium.
| Neurocognitive Disorder | Characteristic MRI / FDG-PET Finding | CSF / Molecular Biomarker Profile | First-Line Pharmacotherapy & Key Contraindications |
|---|---|---|---|
| Alzheimer Disease (AD) | Disproportionate medial temporal lobe (hippocampal & entorhinal cortex) and parietal atrophy | Decreased CSF Abeta-42, increased phosphorylated tau (p-tau) and total tau; APOE epsilon-4 allele | Donepezil, rivastigmine, galantamine (AChEIs) + memantine (NMDA antagonist for moderate-severe); lecanemab (anti-amyloid mAb) |
| Dementia with Lewy Bodies (DLB) | Preserved medial temporal lobe volume; occipital hypometabolism on FDG-PET ('cingulate island sign'); reduced striatal DaTscan uptake | Alpha-synuclein (Lewy body) neuronal inclusions in cortex and substantia nigra | Rivastigmine or donepezil for cognitive/hallucinatory symptoms; pimavanserin or low-dose quetiapine; AVOID high-potency D2 antipsychotics (haloperidol causes severe neuroleptic sensitivity) |
| Frontotemporal Dementia (FTD) | Striking asymmetric frontal and/or anterior temporal ('knife-edge') lobar atrophy | Hyperphosphorylated tau (Pick bodies, 3R/4R tau) or TDP-43 / C9orf72 / FUS inclusions | SSRIs (trazodone, sertraline) for behavioral disinhibition/compulsions; AChEIs do NOT improve FTD and may worsen agitation |
| Normal Pressure Hydrocephalus (NPH) | Ventriculomegaly out of proportion to sulcal enlargement (Evans index > 0.3) with periventricular transependymal edema | Normal opening pressure on lumbar puncture (8-18 cm H2O); gait improves after high-volume (30-50 mL) CSF tap test | Ventriculoperitoneal (VP) shunt placement (gait apraxia is the first and most responsive symptom to improve) |
Cholinesterase Inhibitor & Memantine Pharmacology and Adverse Effect Profiles
Central acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) augment synaptic acetylcholine transmission from the degenerating nucleus basalis of Meynert to the cerebral cortex, providing modest symptomatic stabilization in mild-to-severe Alzheimer disease and Dementia with Lewy Bodies. Because peripheral muscarinic stimulation increases vagal tone and gastrointestinal motility, the most common dose-limiting adverse effects are nausea, vomiting, diarrhea, vivid dreams/insomnia, and sinoatrial bradycardia or heart block (syncope). In moderate-to-severe Alzheimer disease, adding memantine—an uncompetitive, voltage-dependent NMDA glutamate receptor antagonist—blocks pathologic calcium-mediated excitotoxicity without impairing physiological long-term potentiation.
Non-Pharmacologic Delirium Prevention & Beers Criteria Deprescribing
In hospitalized older adults, multicomponent non-pharmacologic orientation protocols (frequent reorientation, preserving sleep-wake cycles, early mobilization, returning eyeglasses and hearing aids, avoiding physical restraints, and removing unnecessary urinary catheters) reduce incident delirium by 30% to 40%. Immediate medication reconciliation using the AGS Beers Criteria must discontinue deliriogenic offenders—specifically first-generation antihistamines (diphenhydramine, hydroxyzine), tricyclic antidepressants, bladder antimuscarinics (oxybutynin), benzodiazepines, and systemic corticosteroids. Physical restraints and benzodiazepines paradoxically worsen non-withdrawal delirium duration and mortality.
COMLEX / OMM Integration
NBOME High-Yield Correlate
Cranial Glymphatic Drainage (CV4), Vagal/Sympathetic Autonomics in Delirium & NPH Pelvic Mechanics
- Glymphatic Clearance & Compression of the Fourth Ventricle (CV4): During slow-wave sleep, the brain's glymphatic system clears extracellular metabolic waste—including β-amyloid (Aβ42) and hyperphosphorylated tau—along perivascular astrocytic aquaporin-4 channels into the dural venous sinuses and cervical lymphatics. Osteopathic Compression of the Fourth Ventricle (CV4) (contacting the squamous occiput medial to the occipitomastoid sutures to resist cranial flexion and encourage extension until a still point is achieved) and venous sinus drainage technique enhance primary respiratory mechanism (PRM) amplitude, facilitate CSF fluctuation, and reduce sympathetic hypertonicity. (Note: CV4 is strictly contraindicated in acute intracranial hemorrhage, space-occupying tumors with elevated ICP, or acute skull fractures!)
- Autonomic Balance in Hospitalized Delirium: Hyperactive delirium and nocturnal sundowning are driven by severe sympathetic hyperactivity (T1–T4) and central vagal/cholinergic withdrawal. Gentle suboccipital release (OA decompression) normalizes vagus nerve (CN X) tone as it exits the jugular foramen, while thoracic paraspinal rib raising and myofascial release calm sympathetic overdrive and reduce hospital delirium incidence without sedating medications.
- Lumbosacral & Pelvic Diaphragm Mechanics in Normal Pressure Hydrocephalus: In NPH ('Wet, Wacky, Wobbly'), patients develop a magnetic apraxic gait (producing compensatory bilateral iliopsoas and piriformis hypertonicity and sacral base restrictions) alongside neurogenic urinary urgency. Treating sacral somatic dysfunctions (S2–S4 pelvic splanchnics), thoracolumbar sympathetics (T12–L2), and the pelvic diaphragm—plus inhibiting the bladder anterior Chapman point (periumbilical) and posterior Chapman point (L2 transverse process)—supports post-VP shunt gait rehabilitation and continence.
Board Traps & Common Distractors
- Thiamine Before Glucose in Suspected Wernicke Encephalopathy: Never administer an intravenous dextrose/glucose bolus to an alcoholic, malnourished, or obtunded patient before administering parenteral IV Thiamine (Vitamin B1)! Glucose metabolism consumes remaining thiamine pyrophosphate stores at pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase, precipitating acute irreversible Wernicke-Korsakoff syndrome.
- Neuroleptic Sensitivity in Dementia with Lewy Bodies (DLB): Never prescribe high-potency D2-blocking antipsychotics (such as Haloperidol or Risperidone) for visual hallucinations or agitation in a patient with Dementia with Lewy Bodies; D2 blockade precipitates life-threatening irreversible parkinsonian rigidity, autonomic collapse, and neuroleptic malignant syndrome. Treat DLB hallucinations with Rivastigmine/Donepezil (or low-dose Quetiapine/Pimavanserin if refractory).
- Benzodiazepine & Anticholinergic Trap in Elderly Delirium: Never administer diphenhydramine, oxybutynin, tricyclic antidepressants, or benzodiazepines (lorazepam) for insomnia or agitation in hospitalized older adults (outside of alcohol/benzodiazepine withdrawal); these Beers Criteria agents worsen central cholinergic deficiency and exacerbate delirium.
- Cerebral Amyloid Angiopathy (CAA) & Lobar Hemorrhage: In an normotensive elderly patient with Alzheimer dementia who presents with an acute spontaneous LOBAR intracerebral hemorrhage (parietal or occipital cortex, sparing the deep basal ganglia), suspect Cerebral Amyloid Angiopathy (Aβ deposition in cortical vessel walls) and avoid unnecessary systemic anticoagulation.
- Normal Pressure Hydrocephalus vs. Alzheimer Hydrocephalus Ex Vacuo: Do not mistake ventriculomegaly from diffuse cortical atrophy (hydrocephalus ex vacuo) for Normal Pressure Hydrocephalus; NPH presents with magnetic gait apraxia FIRST (before incontinence and dementia) and shows disproportionately enlarged ventricles with tight high-convexity sulci and a positive high-volume LP tap test.
- Prion Sterilization Hazard in Creutzfeldt-Jakob Disease: Standard hospital steam autoclaving and formaldehyde fixation do NOT inactivate PrPsc prions; neurosurgical instruments exposed to brain tissue from a CJD patient must be quarantined/discarded or treated with concentrated sodium hydroxide (NaOH) / sodium hypochlorite plus extended high-temperature autoclaving.
Previous Chapter
•
Vol 2: Clinical Ch. 33
Multiple Sclerosis, Movement Disorders & Myasthenia
Vol 2: Clinical Ch. 35
•
Next Chapter
Hemostasis, Platelet Disorders & Coagulopathies
Table of Contents (105 Chapters)
Volume 2: Organ System Clinical Pathology • Chapter 34 of 60